A novel, antibody-based radiopharmaceutical for advanced thyroid cancer
May 25 @ 13:00 – 14:00 CEST
Presenter: Dr Marika Nestor, Department of Immunology, genetics and pathology, Uppsala University, Sweden
Molecular radiotherapy is increasingly becoming a powerhouse in the field of cancer- and radiation therapy. By targeting a structure that is abundant on tumor cells but scarce in healthy tissues, a cancer-targeting molecule labeled with a therapeutic radionuclide can mediate the delivery of radioactivity specifically to cancer cells. This creates a targeted, localized form of radiotherapy that combines the advantages of systemic therapy with therapeutically effective radiation.
In a collaboration with the Drug Discovery & Development platform at Science for Life Laboratory, we have developed an antibody-based radiopharmaceutical for molecular radiotherapy of advanced thyroid carcinoma. The project spans over the whole early development chain; from preclinical innovation in the lab, dosimetry and proof-of-concept in animal models, to upscaled production and preparations for first-in-man studies.
Dr Nestor in her presentation will discuss the process from innovation to implementation of the project, both from a research and a commercialization perspective.
Marika Nestor leads a translational research group at the Department of Immunology, Genetics and Pathology, Uppsala University. Her research group focuses on radionuclide targeting and radiosensitization of cancer cells. She obtained her PhD at Uppsala University in 2006, and became an Associate Professor in 2012. In 2013 she was awarded the Göran Gustafsson prize for young scientists, in 2016 the Junior Investigator Award from the Swedish Cancer Society, and in 2020 the Senior Investigator Award. In 2019, she was awarded a grant from Sweden’s innovation agency VINNOVA to facilitate clinical translation of her findings, as well as an Attractive Innovation Award by UU Innovation.